Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates total enrolment at 750, including ...
No efficacy concern. No safety concern. A launch Sobi valued at SEK 4–6 billion, stopped by a third-party facility. And it was the second of three manufacturing-driven rejections the FDA issued in ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved that early safety, brain exposure and a novel mechanism can still move a small Nordic biotech into a multibillion-dollar ...
Bright scientific image illustrating eplontersen TTR silencing in transthyretin amyloid cardiomyopathy, cardiac amyloid burden and the challenge of adding a silencer to stabilizer therapy. HELIOS-B ...
Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. No safety concern. No efficacy ...
The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed study. Read against the registry it is the sixth attempt to take a rare-disease drug into a large ...
RP1 showed a roughly one-in-three response rate, durable activity, and a favorable safety profile in anti-PD-1-failed advanced melanoma. The FDA rejected it anyway — not because the drug had obviously ...
Merck priced the first oral PCSK9 inhibitor at $10.50 a tablet. Amgen has been selling Repatha, in cash, for roughly eight dollars a day since October. That is the whole trade in two lines, and most ...
Put this method on a file you are actually deciding. Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a ...
A cinematic no-text visual of the Novo Nordisk–Eli Lilly lawsuit, using pharma injectables, medicine vials, legal scales, and blue-orange biotech lighting to show a high-stakes dispute in global ...
A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results